Hogan Lovells advises Novartis in respiratory cell therapy licensing deal with Mesoblast
Washington, D.C., 23 November 2020 – Global law firm Hogan Lovells has advised international pharmaceutical company Novartis in connection with an exclusive worldwide license and collaboration agreement with Mesoblast Limited to develop, commercialize, and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19.
Under the license and collaboration agreement, Novartis will acquire rights to develop, commercialize and manufacture remestemcel-L for ARDS and will obtain access to an innovative cell-therapy platform with a range of potential applications in severe respiratory conditions and beyond.
Novartis will make an upfront payment and equity investment in Mesoblast, with additional payments and royalties due on achievement of agreed development, regulatory, and commercial milestones.
Novartis intends to initiate a Phase III study in non-COVID-19-related ARDS after the anticipated closing of the license and collaboration agreement and successful completion and outcome of the current study.
The Hogan Lovells team was led by New York corporate partner Adam Golden, with support from counsel Penny Powell (London) and senior associate Jeff Jay (New York).
Other key support included global regulatory partners Suyong Kim (London), Leigh Oliver (Washington D.C.), and Edith Ramirez (Washington D.C.) and senior associate Lauren Battaglia (Washington D.C.); BRI partner and Sydney office managing partner Scott Harris; capital markets partner Lillian Tsu (New York) and senior associate Ji Yoon (Chloe) Chung (New York); banking partners Deborah Staudinger (New York) and Frederick Cristman (Washington D.C.); private equity & funds M&A partner David Holland (Sydney) and senior associates Madison Smith (Perth) and Hannah Wilson-Reddy (London); and intellectual property, media, & technology associate Rachel Eisen (Northern Virginia).
The full news release can be accessed here.